Browse the evidence

GLP1/Estrogen (GLP1/E) multi-agonist therapy provides superior metabolic improvement in PCOS models compared to GLP1 monotherapy, dual/triple agonists, and metformin, achieving significant weight loss, fat mass reduction, and improved insulin sensitivity without gastrointestinal distress.

For individuals with PCOS and metabolic issues, GLP1/Estrogen multi-agonist therapy appears to be a highly effective treatment option, significantly outperforming standard care like metformin in reducing weight, fat, and improving insulin sensitivity. While currently studied in mice, this suggests a promising future therapeutic avenue for managing PCOS-related metabolic complications.

Adherence to a Mediterranean diet significantly reduces the incidence of peripheral artery disease (PAD) and improves claudication symptoms through oxidative stress reduction and anti-inflammatory effects.

Adopt a Mediterranean-style eating pattern: use olive oil as your primary cooking fat, eat plenty of vegetables, fruits, legumes, and whole grains, include moderate amounts of fish and dairy, and limit red and processed meats. This approach has been shown to significantly reduce the risk of developing peripheral artery disease and improve walking symptoms in those who already have it.

Intentional weight loss of >5 pounds in patients with intermittent claudication reduces the annual decline in walking distance, independent of muscle loss.

If you have PAD and are overweight, aim to lose more than 5 pounds. This specific amount of weight loss has been shown to help you walk further for longer, even if you lose some leg muscle in the process. Combine this with exercise for best results.

GLP-1 receptor agonists (GLP-1RAs) including semaglutide 2.4 mg and tirzepatide induce significant weight loss (12-20%) and improve metabolic comorbidities, but discontinuation of therapy leads to rapid weight regain, indicating that obesity treatment with these agents requires long-term or lifelong administration.

GLP-1 medications like semaglutide (2.4 mg weekly) and tirzepatide are highly effective for weight loss, achieving 12-20% body weight reduction in clinical trials. However, these drugs treat obesity as a chronic condition; stopping treatment typically leads to rapid weight regain. Therefore, successful long-term management likely requires continuous, lifelong therapy. Side effects like nausea are common but manageable through slow dose escalation. Oral versions are emerging to address injection aversion.

Higher habitual dairy intake causally increases lean body mass in adults, as evidenced by Mendelian randomization analysis of 182,041 individuals.

To support lean mass maintenance or growth, include dairy in your daily diet. The study suggests a causal link between higher dairy intake and increased lean mass. Aim for multiple servings per day if tolerated, as the benefit appears dose-dependent.

Body composition assessment (quantifying fat-free mass, fat mass, and visceral adipose tissue) provides a more accurate assessment of cardiometabolic disease risk than Body Mass Index (BMI) alone, particularly for identifying 'normal weight obesity' and sarcopenic obesity.

Stop relying solely on the scale. If you are maintaining a 'normal' BMI but feel weak or have high blood sugar, ask for a body composition assessment (like DXA or BIA). This will reveal if you have 'normal weight obesity' (high fat, low muscle) or sarcopenic obesity (high fat, low muscle), which are high-risk conditions that BMI misses. Prioritize resistance training and protein intake to build muscle, as this is the most effective way to lower metabolic risk when BMI is misleading.

Visceral Adipose Tissue (VAT) is a stronger predictor of metabolic syndrome and cardiovascular disease risk than total fat mass or BMI, particularly in Asian populations where VAT accumulation occurs at lower BMI thresholds.

Focus on reducing visceral fat, not just total weight. If you are Asian or older, your BMI might be 'normal' while your visceral fat is high. Use waist circumference or body composition scans to monitor VAT. Reducing VAT through exercise and diet is critical for lowering metabolic syndrome risk.

Psychogenic factors, particularly stress and PTSD, are decisive in the development of obesity through mechanisms involving high cortisol and sympathetic overactivity.

If you struggle with stress or PTSD, recognize that these mental health challenges can biologically drive weight gain through cortisol. Addressing mental health through therapy or stress management is a critical part of obesity treatment.

Epigenetic interventions, pharmacotherapy, and bariatric surgery are emerging as important tools for obesity management, alongside lifestyle changes.

Consult with a healthcare provider about advanced treatment options like pharmacotherapy or bariatric surgery if lifestyle changes alone are insufficient. These are valid medical tools, not last resorts.

Bariatric surgery (gastric bypass, sleeve gastrectomy, or adjustable gastric banding) is cost-effective over a 10-year horizon and cost-saving over a lifetime compared to conventional medical management, primarily by reducing the incidence of type 2 diabetes and cardiovascular events.

For obese individuals with BMI >40 (or >35 with Type 2 Diabetes) who have failed conservative weight loss, bariatric surgery is a clinically and economically superior long-term strategy compared to medical management alone. It significantly reduces the risk of diabetes and cardiovascular disease, leading to cost savings and improved quality of life over a lifetime. However, access barriers like insurance restrictions and waiting lists should be minimized, as delays result in lost health benefits.

Equating total training volume, resistance training performed 2 days per week produces similar increases in muscular strength and hypertrophy compared to 3 days per week in resistance-trained men.

If you are an experienced lifter, you do not need to train every muscle group 3+ times a week to maximize gains. As long as you are hitting the same total number of hard sets per week, splitting those sets across 2 days (e.g., Upper/Lower or Push/Pull/Legs) works just as well as hitting them 3 times. Focus on getting your total weekly volume in, rather than obsessing over high frequency.

High baseline insulin secretion predicts greater long-term weight gain, particularly when consuming high-glycemic-index diets, supporting the carbohydrate-insulin model of obesity pathogenesis.

If you have high insulin levels, focus on reducing the glycemic load of your diet. High-glycemic foods may trigger excessive insulin secretion, promoting fat storage and weight gain, especially in those predisposed to insulin resistance.

Increased gut microbiome diversity and high dietary fiber intake are associated with lower long-term weight gain, mediated by short-chain fatty acids (SCFAs) like butyrate.

Increase your intake of dietary fiber to promote a diverse gut microbiome. This can lead to higher levels of beneficial SCFAs like butyrate, which improve insulin sensitivity and may help prevent long-term weight gain.

In overweight and obese women, twice-daily exenatide treatment yields long-term weight loss outcomes similar to a hypocaloric diet with matched placebo injections, with no significant difference in the proportion of super responders (≥10% weight loss).

For overweight women, twice-daily exenatide does not guarantee better long-term weight loss than a strict hypocaloric diet alone. In fact, the study showed similar rates of significant weight loss (≥10%) between the drug and diet groups. The high response in the diet group suggests that the ritual of pre-meal injections may aid adherence. Patients should weigh the burden of daily injections against the potential benefit, as diet alone can be highly effective for early responders.

Ultraprocessed food (UPF) consumption is positively associated with body fat percentage, independent of energy expenditure, age, sex, and economic development rank.

If you are trying to manage body fat, the type of food matters as much as the amount. Ultraprocessed foods are linked to higher body fat even when you account for how much you move. Prioritize whole, minimally processed foods to improve satiety and potentially reduce net energy absorption.

Functional and physiological biomarkers are more suitable for medium- and long-term interventions (≥3 months) than acute or short-term interventions (<3 months).

If you are designing an intervention study to measure aging, ensure the intervention lasts at least 3 months (medium) or 6 months (long). Short-term interventions are unlikely to yield meaningful changes in these biomarkers.

Low-carbohydrate/high-fat diets (e.g., Atkins) primarily result in weight loss through caloric restriction and water loss, not superior metabolic advantages, and may increase long-term mortality risk if animal proteins and fats are used.

If you choose a low-carb diet, be aware that weight loss is likely due to eating fewer calories and losing water weight, not magic metabolism. Also, be cautious of long-term risks associated with high animal protein/fat intake.

Low-carbohydrate diets (<40% energy) are at least as effective as low-fat diets for short-term weight loss and improve triglyceride and HDL cholesterol profiles, but they increase total and LDL cholesterol levels.

If you choose a low-carb diet for weight loss, expect better triglyceride and HDL improvements than a low-fat diet, but monitor your LDL cholesterol closely as it may rise. The weight loss benefit is real in the short term (under 1 year).

In Korean populations, high carbohydrate intake (50-80% of energy) is associated with an increased risk of metabolic syndrome, elevated triglycerides, and lower HDL cholesterol, but a reduced risk of elevated total and LDL cholesterol.

If you eat a traditional Korean high-carb diet, be aware that high carb intake correlates with higher triglycerides and lower HDL. However, it may keep LDL lower. Focus on improving the quality of your carbohydrates (whole grains) rather than just cutting them.

Moderate carbohydrate intake (50-60% of energy) is associated with the lowest all-cause mortality risk, forming a U-shaped relationship where both very low (<40%) and very high (>70%) intakes increase mortality risk.

Aim for 50-60% of your calories from carbohydrates for optimal longevity. Both very low and very high carbohydrate intakes are associated with higher mortality risks.

Amateur bodybuilders in the pre-contest period experience significantly increased oxidative stress, inflammation, and upper respiratory tract infection severity due to severe caloric restriction and macronutrient deficits.

If you are cutting calories drastically for a competition, expect your immune system and recovery to suffer. This study shows that severe energy restriction (45% deficit) combined with high training volume leads to increased oxidative stress and inflammation, even if you eat enough protein. To mitigate this, ensure you are getting enough micronutrients (especially Vitamins A and E) and healthy fats, as their deficiency was linked to higher oxidative damage. Be aware that using anabolic steroids, common in this population, may mask some symptoms but does not eliminate the underlying oxidative stress.

Severe caloric restriction in bodybuilders leads to micronutrient deficiencies (specifically Vitamins A and E) which correlate with increased oxidative stress and reduced antioxidant enzyme activity.

When cutting calories, do not neglect micronutrients. This study found that 75% of bodybuilders failed to meet the Recommended Daily Allowance for Vitamin E during their cut. This deficiency was strongly correlated with higher oxidative stress. Ensure your diet includes sufficient sources of Vitamins A and E, and adequate dietary fats to aid absorption, as fat intake was also severely restricted.

Pre-contest bodybuilding preparation is associated with worsened psychological status, including increased fatigue, mood disturbance, and perceived stress, alongside reduced recovery.

Be prepared for mental fatigue and mood swings during your cut. This study shows that total mood disturbance increases by 35% and fatigue by 23% during the pre-contest phase. This is likely due to the combination of low energy availability and high training stress. Prioritize sleep and stress management strategies, as perceived recovery drops significantly.

In Type 2 Diabetes, the adoption of newer glucose-lowering medications (GLP-1 agonists and SGLT2 inhibitors) is associated with a significant decline in fracture incidence rates, particularly in men and women under 50 and over 70.

If you have Type 2 Diabetes, discuss with your doctor whether your current medication increases your fracture risk. The data suggests that switching to newer classes of drugs, specifically GLP-1 agonists or SGLT2 inhibitors, is associated with a significant reduction in fracture rates compared to older medications like sulfonylureas.